Related Experiment Video
Updated: Jun 27, 2026
08:26
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
Published on: October 19, 2021
A staged zebrafish-mouse screening strategy for antiseizure compound prioritization
Charleston F Christie1, Emmaline Bendell1, Ludivine Renaud2
1Neuroene Therapeutics, Kensington, MD, 20895, USA.
Neuropharmacology
|June 25, 2026
Summary
Screening antiseizure medications (ASMs) in later-stage zebrafish (7, 14, and 21 days post-fertilization) improves the identification of compounds with blood-brain barrier (BBB) penetration for epilepsy treatment. This method aids in prioritizing effective CNS-active drugs.
Area of Science:
- Neuroscience and Pharmacology
- Drug Discovery and Development
Background:
- Epilepsy impacts over 50 million globally, necessitating novel antiseizure medications (ASMs).
- Achieving adequate blood-brain barrier (BBB) penetration is a critical challenge for CNS-active ASMs.
- Current pentylenetetrazol (PTZ)-induced zebrafish models often use early larval stages, potentially missing BBB maturation effects.
Purpose of the Study:
- To assess if staged testing in 7-, 14-, and 21-day post-fertilization (dpf) zebrafish enhances CNS-active compound prioritization.
- To identify Vitamin K (VK) analogs with potential antiseizure activity and BBB penetration.
- To validate zebrafish findings in mammalian seizure models.
Main Methods:
- Screened 31 Vitamin K (VK) analogs in 7-dpf zebrafish using PTZ-induced hyperlocomotor activity.
- Advanced promising compounds to dose-response studies in 14- and 21-dpf zebrafish.
- Evaluated selected compounds in the mouse 6 Hz seizure model and performed brain-to-plasma pharmacokinetic analysis.
Main Results:
- Seventeen VK analogs reduced PTZ-induced activity in 7-dpf zebrafish; two retained efficacy in older zebrafish.
- Both validated compounds offered protection in the mouse 6 Hz model, with one effective at higher intensity.
- Brain-to-plasma ratios confirmed CNS exposure for the two most promising compounds (3d and 3l).
Conclusions:
- Later-stage zebrafish screening (up to 21 dpf) is a viable phenotypic step for prioritizing CNS-active antiseizure compounds.
- This approach aids in selecting compounds with potential blood-brain barrier penetration before costly mammalian studies.
- Further pharmacokinetic/pharmacodynamic characterization and direct mammalian validation are essential for drug development.
